Türkiye Ürtiker Tanı ve Tedavi Kılavuzu Baz Alınarak Kliniğimizde Tedavi Edilen Kronik Ürtikerli Hastaların Basamak Tedavisine Göre Dağılımı
Yıl 2021,
Cilt: 11 Sayı: 1, 110 - 112, 30.01.2021
Fatma Tuncez Akyurek
,
Nihal Sari
Gülcan Saylam Kurtipek
,
Gözde Ulutaş Demirbaş
Emre Zekey
,
Mehmet Akyürek
Neriman Akdam
Öz
Amaç: Kronik ürtiker, uzun süreli tedavi gerektiren bir durumdur. Son yıllarda birçok ülke ürtiker tanı ve tedavi yaklaşımlarını bir algoritmada değerlendirmek için kendi kılavuzlarını oluşturmuştur. Bu çalışmada, kliniğimizde tedavi gören kronik ürtikerli hastaların "Türkiye Ürtiker Tanı ve Tedavi Rehberi" tedavi algoritmasına göre dağılımını değerlendirmeyi amaçladık.
Gereç ve Yöntem: Selçuk Üniversitesi Deri ve Zührevi Hastalıklar Anabilim Dalı'na başvuran ve kronik ürtiker tanısıyla takip edilen ve tedavi gören hastaların dosyaları incelendi.
Bulgular: Çalışmaya anjiyoödemi olmayan toplam 102 kronik ürtiker hastası dahil edildi. Bu kılavuza göre hastaların% 17,6'sı standart doz antihistamin tedavisine yanıt verirken, hastaların% 15,7'sinde verilen antihistamin dozu artırıldı. Hastaların% 5.7'sinin antihistamin tedavisi, öncekiyle aynı dozda farklı bir antihistamin grubu ile değiştirildi. Hastaların% 52'si 28 günde bir 300 mg / subkutan omalizumab tedavisine yanıt verdi. Ancak hastaların% 7,8'i 14 günde bir omalizumab tedavisi almış veya omalizumab tedavisine siklosporin tedavisi eklenmesi gerekmiştir. Standart tedaviler dışındaki diğer tedavilere yanıt hastaların% 1'inde alınmıştır.
Sonuç: Çalışmamızın, kronik ürtiker hastalarının tedavi algoritmasına göre dağılımına ışık tutarak klinik pratikte hastaların tedavi yanıtlarını tahmin etmeyi kolaylaştıracağına inanıyoruz.
Kaynakça
- Referans1. Maurer, M., et al., Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy, 2011. 66(3): p. 317-30.
- Referans2. Bernstein, J.A., et al., The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol, 2014. 133(5): p. 1270-7.
- Referans3. Goncu, E.K., et al., The Turkish Guideline for the Diagnosis and Management of Urticaria-2016. Turkderm-Turkish Archives of Dermatology and Venerology, 2016. 50(3): p. 82-98.
- Referans4. Kocaturk, E. and T. Zuberbier, New biologics in the treatment of urticaria. Curr Opin Allergy Clin Immunol, 2018. 18(5): p. 425-431.
- Referans5. Zuberbier, T., et al., The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy, 2018. 73(7): p. 1393-1414.
- Referans6. Marin-Cabanas, I., et al., Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines. Actas Dermosifiliogr, 2017. 108(4): p. 346-353.
- Referans7. Kibsgaard, L., et al., A case series study of eighty-five chronic spontaneous urticaria patients referred to a tertiary care center. Ann Dermatol, 2014. 26(1): p. 73-8.
- Referans8. Maurer, M., et al., Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol, 2017. 31(6): p. 1056-1063.
- Referans9. Wang, L., et al., Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria. Curr Med Res Opin, 2018. 34(1): p. 35-39.
- Referans10. Erdem, Y., et al., The Etiological Evaluation of Patients with Chronic Urticaria. The Medical Bulletin of Sisli Etfal Hospital, 2018. 0(0).
Turkey Urticaria Diagnosis and Treatment Guide based; Distribution of Chronic Urticaria Patients Treated in Our Clinic According to Step Therapy
Yıl 2021,
Cilt: 11 Sayı: 1, 110 - 112, 30.01.2021
Fatma Tuncez Akyurek
,
Nihal Sari
Gülcan Saylam Kurtipek
,
Gözde Ulutaş Demirbaş
Emre Zekey
,
Mehmet Akyürek
Neriman Akdam
Öz
Aim: Chronic urticaria is a condition that requires long-term treatment. In recent years, many countries have created their own guides to evaluate urticaria diagnosis and treatment approaches in an algorithm. In this study, we aimed to evaluate the distribution of patients with chronic urticaria treated in our clinic according to the treatment algorithm the "Turkey Urticaria Diagnosis and Treatment Guide"
Material and Method: The files of the patients who applied to the Department of Dermatology and Venereal Diseases at Selcuk University and were followed up and treated with the diagnosis of chronic urticaria were investigated.
Results: A total of 102 chronic urticaria patients without angioedema were included in the study. According to this guide, 17.6% of patients responded with standard dose antihistamine therapy, while the antihistamine dose given in 15.7% of patients was increased. The antihistamine treatment of 5.7% of patients was replaced by a different group of antihistamines at the same dose as the previous one. 52% of patients responded to omalizumab 300 mg / subcutaneous treatment every 28 days. However, 7.8% of the patients received omalizumab treatment every 14 days or cyclosporine treatment was required to be added to omalizumab treatment. Response to other treatments other than standard treatments was received in 1% of patients.
Conclusion: We believe that our study will facilitate predicting the treatment responses of patients in clinical practice by shedding light on the distribution of chronic urticaria patients according to the treatment algorithm.
Kaynakça
- Referans1. Maurer, M., et al., Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy, 2011. 66(3): p. 317-30.
- Referans2. Bernstein, J.A., et al., The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol, 2014. 133(5): p. 1270-7.
- Referans3. Goncu, E.K., et al., The Turkish Guideline for the Diagnosis and Management of Urticaria-2016. Turkderm-Turkish Archives of Dermatology and Venerology, 2016. 50(3): p. 82-98.
- Referans4. Kocaturk, E. and T. Zuberbier, New biologics in the treatment of urticaria. Curr Opin Allergy Clin Immunol, 2018. 18(5): p. 425-431.
- Referans5. Zuberbier, T., et al., The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy, 2018. 73(7): p. 1393-1414.
- Referans6. Marin-Cabanas, I., et al., Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines. Actas Dermosifiliogr, 2017. 108(4): p. 346-353.
- Referans7. Kibsgaard, L., et al., A case series study of eighty-five chronic spontaneous urticaria patients referred to a tertiary care center. Ann Dermatol, 2014. 26(1): p. 73-8.
- Referans8. Maurer, M., et al., Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol, 2017. 31(6): p. 1056-1063.
- Referans9. Wang, L., et al., Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria. Curr Med Res Opin, 2018. 34(1): p. 35-39.
- Referans10. Erdem, Y., et al., The Etiological Evaluation of Patients with Chronic Urticaria. The Medical Bulletin of Sisli Etfal Hospital, 2018. 0(0).